Monash & Virtus see market growth return

After a painful year, demand for assisted reproductive services is growing again. But it's the long term that matters.

This time last year, Monash IVF reported that total patient treatments in its key markets had fallen 3.7% on the prior year, compared to the 4% market growth assumed in its prospectus. Monash’s share price dropped 15%, while the stock of larger competitor Virtus Health fell 8%.

However, we considered the result ‘simply a short-term blip spurred by softer than expected industry figures’ and maintained our Buy recommendation (see Virtus Health and Monash still buys from 30 Oct 14 (Buy – $1.37)).


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles